Cargando…
Covid-19 vaccine immunogenicity in people living with HIV-1
INTRODUCTION: COVID-19 vaccine efficacy has been evaluated in large clinical trials and in real-world situation. Although they have proven to be very effective in the general population, little is known about their efficacy in immunocompromised patients. HIV-infected individuals’ response to vaccine...
Autores principales: | Nault, Lauriane, Marchitto, Lorie, Goyette, Guillaume, Tremblay-Sher, Daniel, Fortin, Claude, Martel-Laferrière, Valérie, Trottier, Benoît, Richard, Jonathan, Durand, Madeleine, Kaufmann, Daniel, Finzi, Andrés, Tremblay, Cécile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069249/ https://www.ncbi.nlm.nih.gov/pubmed/35568588 http://dx.doi.org/10.1016/j.vaccine.2022.04.090 |
Ejemplares similares
-
Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
por: Marchitto, Lorie, et al.
Publicado: (2023) -
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020) -
High frequencies of adaptive NK cells are associated with absence of coronary plaque in cytomegalovirus infected people living with HIV
por: Alsulami, Khlood, et al.
Publicado: (2022) -
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Tauzin, Alexandra, et al.
Publicado: (2022) -
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2021)